NOVEL Health Strategies CHARTS: Top 20 Medicare Drugs by Per User Spending; PAH, HCV and Oncology Dominate
We recently analyzed the Medicare Part D and B 2014 data to review the per user spending. Interestingly, the no. 1 and 2 drugs are indicated for pulmonary arterial hypertension (PAH). No. 3 was Sovaldi at $94K. Interestingly, the per user spending for Harvoni is almost 36% lower than Sovaldi. The drugs in top 10 are either indicated for PAH, hepatitis C or cancer. Another interesting one was Hizentra (at no. 13) for primary immunodeficiency disorders.